STOCKS TELEGRAPH

Tag: INMB stock

  • After-Market Momentum: INmune Bio (INMB) Shares Leap On Clinical Trial News

    After-Market Momentum: INmune Bio (INMB) Shares Leap On Clinical Trial News

    During extended trading hours, INmune Bio, Inc. (NASDAQ: INMB) had a notable spike, with its shares rising 83.28% to $11.51. This upswing followed a regular session decline of 14.79%, where INMB stock closed at $6.28. Following the company’s release of impending findings from its Phase 2 MINDFuL clinical study, which targets early Alzheimer’s Disease (AD), a significant milestone in its research pipeline, there was turbulence.

    Upcoming Conference Call and Trial Overview

    On Monday, June 30, INmune Bio (INMB) will have a conference call to provide the top-line results of the Phase 2 MINDFuL study, which assesses the effectiveness of its experimental medication, XPro, in treating individuals with early-stage Alzheimer’s disease. INmune Bio showcased baseline data and participant biomarker profiles at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) in Vienna earlier this year, where it revealed first findings.

    With an average participant age of 72, the MINDFuL experiment is a blinded, randomized research that includes people with moderate AD or mild cognitive impairment (MCI). Over the course of 23 weeks, subjects were randomized in a 2:1 ratio to receive weekly subcutaneous injections of either 1.0 mg/kg of XPro or a placebo.

    Trial Endpoints and Patient Characteristics

    The primary endpoint of the trial is the change in cognitive performance using the Early and Mild Alzheimer’s Cognitive Composite (EMACC), a tool specifically designed for early-stage AD trials. EMACC scores at baseline were higher in MCI patients and strongly correlated with other validated scales like MMSE and CDR-SB. Notably, 69.2% of participants were APOE ε4 carriers, and 64.4% met inclusion criteria for more than one inflammatory biomarker.

    Secondary Measures and Future Updates

    Secondary outcomes include assessments using CDR-SB, E-Cog, ADL, the Neuropsychiatric Inventory (NPI), blood-based biomarkers, and neuroimaging. The patient cohort showed remarkable similarity to those in successful Phase III studies. INmune Bio (INMB) had previously indicated plans to release topline MINDFuL trial results by June, a catalyst that has now ignited renewed investor interest in its shares.

  • INmune Bio, Inc. (INMB) Stock on the Rise Following First Patient Treatment in INKmune Phase 1 Clinical Trial

    INmune Bio, Inc. (INMB) stock prices were up by 12.67% as of the market closing on July 13th, 2021, bringing the price per share up to USD$26.68. Subsequent premarket fluctuations saw the stock rise by 7.01%, bringing it up to USD$28.55.

    INKmune

    July 12th, 2021 saw the company announce the use of INKmune, its Natural Killer (NK) cell priming platform, had been used to treat the first patient in Phase 1 clinical trial. The treatment is being explored as a viable option for patients with high-risk myelodysplastic syndrome. MDS is a hematopoietic stem cell disorder that is indicated by functionally defective NK cells, with the level of dysfunction being predictive of overall survival. Roughly 33% of MDS cases develop into acute myelogenous leukemia (AML). With no known cure for MDS, existing therapies like chemotherapy and bone marrow/stem cell transplantation have varying degrees of success.

    Research Conducted

    With levels of NK function in MDS patients being predictive of overall survival, 15 years of lab research into potential patient treatment has raised hopes. The enhancement of low-level NK activity in patients with poor prognosis to the level of those with better overall survival, thereby altering the course of the disease, could be highly commercially promising.

    Scope of Research

    Lab work has shown INKmune binding to multiple NK receptors and initiates the activation of more than 3000 genes associated with function, trafficking, proliferation, and overall survival. With not a single cytokine available that has such a myriad of physiological effects, INKmune is being referred to as a psuedokine.

    Expanded Opportunities

    The treatment of the first patient in the trial serves as a major milestone, with the company being the first to study the INKmune platform in a formal clinical setting. With it being widely known that dysfunctional NK cells in cancer patients are not effective at eradicating residual disease after chemotherapy, leading to relapse and poor outcomes. The company has shown that with the delivery of tumor-specific activating signals to NK cells with INKmune, autologous tumor killing can be initiated.

    Future Outlook for INMB

    Armed with the significant milestone of having treated the first patient in the study, INMB is poised to capitalize on the opportunities afforded to it as a result. The company is keen to push for the accelerated development and eventual commercialization and proliferation of the treatment. Current and potential investors are hopefully that management will continue to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.